ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 161.3 DKK 4.2% Market Closed
Market Cap: 35.7B DKK
Have any thoughts about
ALK-Abello A/S?
Write Note
Section:
 

Relative Value

The Relative Value of one ALK B stock under the Base Case scenario is 197.9 DKK. Compared to the current market price of 161.3 DKK, ALK-Abello A/S is Undervalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALK B Relative Value
Base Case
197.9 DKK
Undervaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.6
P/S
P/S
Price to Sales
6.6
vs History
42
vs Industry
20
Median 3Y
6.1
Median 5Y
5.9
Industry
2.5
Forward
6.2
More Details
45.5
P/E
P/E
Price to Earnings
45.5
vs History
71
vs Industry
6
Median 3Y
59.4
Median 5Y
57.1
Industry
21.8
Forward
43
More Details
32.9
P/OCF
P/OCF
Price to OCF
32.9
vs History
74
vs Industry
10
Median 3Y
47.8
Median 5Y
46.5
Industry
16.1
More Details
71.4
P/FCFE
P/FCFE
Price to FCFE
71.4
vs History
41
vs Industry
4
Median 3Y
71.7
Median 5Y
10.8
Industry
23.8
More Details
7
P/B
P/B
Price to Book Value
7
vs History
44
vs Industry
9
Median 3Y
6.7
Median 5Y
6.5
Industry
2.1
More Details
6.6
EV/S
EV/S
Enterprise Value to Sales
6.6
vs History
42
vs Industry
19
Median 3Y
6.2
Median 5Y
6
Industry
2.7
Forward
6.2
More Details
10.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.3
vs History
42
vs Industry
18
Median 3Y
9.9
Median 5Y
9.5
Industry
5.2
More Details
26.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
26.6
vs History
63
vs Industry
9
Median 3Y
31.6
Median 5Y
29.4
Industry
13.5
Forward
24.2
More Details
33
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
33
vs History
76
vs Industry
9
Median 3Y
43.3
Median 5Y
45
Industry
16.8
Forward
29.9
More Details
32.8
EV/OCF
EV/OCF
Enterprise Value to OCF
32.8
vs History
74
vs Industry
10
Median 3Y
49.3
Median 5Y
47
Industry
15.2
More Details
45.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
45.8
vs History
69
vs Industry
6
Median 3Y
154.1
Median 5Y
113.7
Industry
19.3
More Details
5.5
EV/IC
EV/IC
Enterprise Value to IC
5.5
vs History
28
vs Industry
17
Median 3Y
4.7
Median 5Y
4.5
Industry
1.9
More Details

Multiples Across Competitors

ALK B Competitors Multiples
ALK-Abello A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
ALK-Abello A/S
CSE:ALK B
35.7B DKK 6.6 45.5 26.6 33
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 17.8 87.1 46.9 52.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK 9.6 27.5 19.1 21.8
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
248.3B USD 3.9 20.4 10.3 12.4
CH
Roche Holding AG
SIX:ROG
197.2B CHF 3.4 17.2 9.7 11.5
UK
AstraZeneca PLC
LSE:AZN
159B GBP 4.1 31 169.2 253.5
CH
Novartis AG
SIX:NOVN
169.7B CHF 3.8 10.8 9.4 13
US
Pfizer Inc
NYSE:PFE
149.4B USD 2.5 35.1 10.5 15.8
P/S Multiple
Revenue Growth P/S to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average P/S: 382 942.4
6.6
51%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
17.8
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
3.9
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average P/E: 33.1
45.5
180%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
87.1
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
27.5
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.4
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.2
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.1
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBITDA: 415.9
26.6
138%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.9
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.3
331%
0
CH
Roche Holding AG
SIX:ROG
9.7
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.2
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBIT: 1 813.1
33
176%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
21.8
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.5
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.5
131%
1.9
CH
Novartis AG
SIX:NOVN
13
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2

See Also

Summary
ALK B intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALK B stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALK B stock valuation using valuation multiples.
Wall Street Estimates
ALK B price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALK B stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.